Scientific advances and increased awareness of the effect of testosterone deficiency (hypogonadism) on both sexual and general health reinforce the importance of managing testosterone deficiency (hypogonadism) effectively for the benefit of patients.

BSSM guidelines on adult testosterone deficiency, with statements for
UK practice1

These statements have been developed for UK practice and aim to address the widespread media and scientific concerns over the appropriate treatment of men with testosterone deficiency with testosterone therapy. Written by the BSSM (British Society for Sexual Medicine) panel

Read more Download

A practical guide from the BSSM on the assessment and management of testosterone deficiency in adult men1

This guide aims to provide a quick reference for UK healthcare professionals to recognise the issue and to manage the patients proactively and appropriately, based on the 2017 BSSM guidelines on adult testosterone deficiency, with statements for UK practice. Provided by the BSSM (British Society for Sexual Medicine)

Read more Download

Several international medical societies have issued recommendations on the diagnosis, treatment and monitoring of men with hypogonadism. We have included links to these guidelines along with a summary of the main points for the clinician to consider on the clinical guidelines for treatment of hypogonadism with testosterone therapy page.

Recommendation on the diagnosis, treatment and monitoring of hypogonadism in men

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud.

Read more Download
EAU Guidelines on Male Hypogonadism

Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging.

Read more Download

Clinical guidelines for treatment of hypogonadism with testosterone therapy

Read more

References

  • Hackett G et al. The British Society for Sexual Medicine guidelines on adult testosterone deficiency with statements for UK practice. J Sex Med 2017;14:1504- 23. Return to content

Nebido® (testosterone undecanoate) is contraindicated in men with androgen-dependent carcinoma of the prostate. Careful and regular monitoring of the prostate gland must be performed in accordance with recommended methods (digital rectal examination and serum PSA measurement) in patients receiving testosterone replacement therapy, especially in elderly and at risk patients. Local guidelines for safety monitoring should be taken into consideration. Please refer to the Summary of Product Characteristics for full details https://www.bayer.co.uk/en/our-products.

Keep up-to-date with the guidelines on men's health.

CPD accredited online module to help you manage your male patients’ health.

Useful testosterone tools for the evaluation and management of your male patients.

Join 2,000 healthcare professionals and don’t miss out on the latest news.

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk.

Adverse events should also be reported to Bayer plc, Tel: 01182063500, Fax: 01182063703, Email: pvuk@bayer.com.

If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc, Email: qualitycomplaints@bayer.com

For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.